Moreover, lirafugratinib, a potent and highly selective FGFR2 inhibitor, is currently undergoing clinical trials for treatment of metastatic cholangiocarcinoma or other malignant solid tumors [33,34], holding promise as a therapeutic option for ccRCC. Here, FGFR2 is linked to nonpapillary renal cell carcinoma.